Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Precision BioSciences, Inc.

http://www.precisionbiosciences.com

Latest From Precision BioSciences, Inc.

Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans

SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal

Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.

Commercial Companies

Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche

The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.

ImmunoOncology Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Elo Life Systems
    • Precision PlantSciences
UsernamePublicRestriction

Register